Embecta Corp Stock Fair Value Calculation – EMBECTA CORP Reports 2.7% Year-Over-Year Increase in Total Revenue for FY2023 Q4
December 6, 2023
☀️Earnings Overview
EMBECTA CORP ($NASDAQ:EMBC) reported total revenue of USD 281.9 million for the fourth quarter of FY2023, ending September 30 2023, a 2.7% year-over-year increase. Net income rose 134.9% year-over-year to USD 6.0 million, with these earnings results announced on November 21 2023.
Analysis – Embecta Corp Stock Fair Value Calculation
GoodWhale has conducted an analysis of EMBECTA CORP‘s wellbeing, and with our proprietary Valuation Line, we have calculated the intrinsic value of EMBECTA CORP’s stock to be around $30.7. This is significantly higher than the current market price of $17.1, meaning that the stock is undervalued by 44.3%. This presents a great opportunity for investors as the potential for profitability is high. GoodWhale recommends investing in EMBECTA CORP as it is currently undervalued. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Embecta Corp. More…
| Total Revenues | Net Income | Net Margin |
| 1.12k | 70.4 | 6.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Embecta Corp. More…
| Operations | Investing | Financing |
| 67.7 | -26.5 | -48.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Embecta Corp. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.21k | 2.04k | -14.33 |
Key Ratios Snapshot
Some of the financial key ratios for Embecta Corp are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 1.1% | -22.8% | 19.0% |
| FCF Margin | ROE | ROA |
| 3.7% | -16.3% | 10.9% |
Peers
The company was founded in 1980 and is headquartered in New York, NY. Embecta Corp‘s products include prescription drugs for the treatment of cardiovascular disease, diabetes, and cancer. The company’s competitors include Uluru Inc, RxSight Inc, and Modalis Therapeutics Corp.
– Uluru Inc ($OTCPK:ULUR)
RxSight Inc is a medical device company that develops and commercializes innovative ophthalmic implants that allow ophthalmologists to more precisely treat complex retinal diseases. As of 2022, the company has a market capitalization of 318.4 million and a return on equity of -31.3%.
– RxSight Inc ($NASDAQ:RXST)
Modalis Therapeutics Corp is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of cancer and other diseases. The company has a market cap of 11.21B as of 2022 and a return on equity of -13.14%. Modalis Therapeutics Corp is headquartered in New York, New York.
Summary
EMBECTA CORP reported strong financial results for the fourth quarter of FY2023, with a total revenue of USD 281.9 million and a net income of USD 6.0 million, representing a 2.7% and 134.9% year-over-year increase respectively. On the same day as the announcement, the stock price of EMBECTA CORP experienced a positive movement. This news allows investors to view the company as a potential lucrative investment, as the strong financial performance reflects the overall financial strength of the company. Therefore, investors could find EMBECTA CORP an attractive investment opportunity, given its potential for growth and stability.
